Phase I study of PSMA-targeted docetaxel-containing nanoparticle BIND-014 in patients with advanced solid tumors

Daniel D. Von Hoff, Monica M. Mita, Ramesk K Ramanathan, Glen J. Weiss, Alain C. Mita, Patricia M. Lorusso, Howard A. Burris, Lowell L. Hart, Susan C. Low, Donald M. Parsons, Stephen E. Zale, Jason M. Summa, Hagop Youssoufian, Jasgit C. Sachdev

Research output: Contribution to journalArticle

98 Scopus citations

Abstract

Purpose: First-in-human phase I trial to determine the safety, pharmacokinetics, and antitumor activity of BIND-014, a novel, tumor prostate-specific membrane antigen (PSMA)-targeted nanoparticle, containing docetaxel. Experimental Design: Patients with advanced solid tumors received BIND-014 every three weeks (n = 28) or weekly (n = 27), with dose levels ranging from 3.5 to 75 mg/m2 and 15 to 45 mg/m2, respectively. Results: BIND-014 was generally well tolerated, with no unexpected toxicities. The most common drug-related toxicities (>20% of patients) on either schedule included neutropenia, fatigue, anemia, alopecia, and diarrhea. BIND-014 demonstrated a dose-linear pharmacokinetic profile, distinct from docetaxel, with prolonged persistence of docetaxel-encapsulated circulating nanoparticles. Of the 52 patients evaluable for response, one had a complete response (cervical cancer on the every three week schedule) and five had partial responses (ampullary adenocarcinoma, non-small cell lung, and prostate cancers on the every-three-week schedule, and breast and gastroesophageal cancers on the weekly schedule). Responses were noted in both PSMA-detectable and -undetectable tumors. Conclusions: BIND-014 was generally well tolerated, with predictable and manageable toxicity and a unique pharmacokinetic profile compared with conventional docetaxel. Clinical activity was noted in multiple tumor types. The recommended phase II dose of BIND-014 is 60 mg/m2 every three weeks or 40 mg/m2 weekly.

Original languageEnglish (US)
Pages (from-to)3157-3163
Number of pages7
JournalClinical Cancer Research
Volume22
Issue number13
DOIs
StatePublished - Jul 1 2016

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase I study of PSMA-targeted docetaxel-containing nanoparticle BIND-014 in patients with advanced solid tumors'. Together they form a unique fingerprint.

  • Cite this

    Von Hoff, D. D., Mita, M. M., Ramanathan, R. K., Weiss, G. J., Mita, A. C., Lorusso, P. M., Burris, H. A., Hart, L. L., Low, S. C., Parsons, D. M., Zale, S. E., Summa, J. M., Youssoufian, H., & Sachdev, J. C. (2016). Phase I study of PSMA-targeted docetaxel-containing nanoparticle BIND-014 in patients with advanced solid tumors. Clinical Cancer Research, 22(13), 3157-3163. https://doi.org/10.1158/1078-0432.CCR-15-2548